{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Pophali P"],"funding":["National Center for Advancing Translational Sciences","NCATS NIH HHS"],"pagination":["1347-1357"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6196105"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["93(11)"],"pubmed_abstract":["In a 28-year period, 39 (7%) patients with chronic myelomonocytic leukemia (CMML) (median age 66 years, 64% male) underwent a splenectomy at our institution. Primary indications for splenectomy were refractory thrombocytopenia (36%), progressive spleen related symptoms (33%), emergent splenectomy for splenic rupture (21%), refractory anemia (8%), and prior to allogeneic stem cell transplant (3%). Eleven (28%) patients had anemia at the time of splenectomy, of which 3 (27%) were autoimmune. The median time to splenectomy from CMML diagnosis was 6 months (0-40); perioperative morbidity and mortality rates were 43% and 13%, while the median postsplenectomy survival was 25 months (11-38). Durable remission in spleen related symptoms, thrombocytopenia, complications from splenic rupture, and an"],"journal":["American journal of hematology"],"pubmed_title":["Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients."],"pmcid":["PMC6196105"],"funding_grant_id":["UL1 TR002377","KL2 TR000136","KL2 TR002379"],"pubmed_authors":["Finke CM","Ketterling RP","Tefferi A","Pophali P","Horna P","Gangat N","Lasho TL","Nagorney D","Patnaik MM"],"additional_accession":[]},"is_claimable":false,"name":"Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients.","description":"In a 28-year period, 39 (7%) patients with chronic myelomonocytic leukemia (CMML) (median age 66 years, 64% male) underwent a splenectomy at our institution. Primary indications for splenectomy were refractory thrombocytopenia (36%), progressive spleen related symptoms (33%), emergent splenectomy for splenic rupture (21%), refractory anemia (8%), and prior to allogeneic stem cell transplant (3%). Eleven (28%) patients had anemia at the time of splenectomy, of which 3 (27%) were autoimmune. The median time to splenectomy from CMML diagnosis was 6 months (0-40); perioperative morbidity and mortality rates were 43% and 13%, while the median postsplenectomy survival was 25 months (11-38). Durable remission in spleen related symptoms, thrombocytopenia, complications from splenic rupture, and an","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Nov","modification":"2025-04-04T01:45:43.819Z","creation":"2019-11-07T08:01:35Z"},"accession":"S-EPMC6196105","cross_references":{"pubmed":["30105755"],"doi":["10.1002/ajh.25246"]}}